Hero Finding
Rare disease patients and caregivers were 2.7 times as likely as oncology patients to report an initial diagnosis that was later revised, and 28% waited more than a year for a confirmed diagnosis.
The cohort contrast the study was built around turned out to be the headline. Oncology journeys are comparatively fast: 76% of oncology patients reached a confirmed diagnosis within three months of first symptoms, and only 3% took more than a year. Rare disease journeys are structurally different: only 44% resolved within three months, 28% took more than a year, and 13% took more than five years. The diagnostic odyssey that rare disease advocacy describes anecdotally showed up in the data as a measurable, significant gap.
Share of each cohort reporting a revised initial diagnosis and a journey past one year · % of n=120 per cohort · stat-tested
Key Findings
What the journey data surfaced.
Six signals mapped where the diagnostic journey loses time, which patient population loses it, and where communication around genetic testing breaks down.
The rare disease diagnostic journey is structurally longer, and the data measured it.
76% of oncology patients reached a confirmed diagnosis within three months of first symptoms, and only 3% took more than a year. Only 44% of rare disease journeys resolved within three months; 28% took more than a year, and 13% took more than five years. The lost time the rare disease community describes anecdotally registered as a significant, structural cohort difference.
Misdiagnosis is the mechanism behind much of the lost time.
Across the full base, 33% of respondents reported an initial diagnosis that was later revised or changed. In the rare disease cohort that figure was 48%, against 18% for oncology, a significant separation. Nearly half of rare disease patients were first given a diagnosis that had to be revised, which frames earlier genome-scale testing as a way to break referral loops rather than as an incremental test-menu upgrade.
Rare disease respondents reported significantly more friction on six of the fourteen barriers measured.
Specialist wait times (27% vs 13%), long waits for results (25% vs 14%), cost and insurance barriers (17% vs 8%), geographic distance to testing (18% vs 6%), unclear or confusing results (15% vs 7%), and being sent down the wrong path initially (15% vs 5%). The friction concentrates in the cohort whose journey is already longest.
Once genetic testing happens, it lands as a decisive event.
Among treated respondents, 76% said the results influenced their treatment, monitoring, or care plan, and 50% called that influence major. The effect was strongest where results steer decisions most directly: 58% of rare disease respondents reported major influence, as did 64% of lung cancer patients against 32% of breast cancer patients, both significant.
The operational gap sits in turnaround.
89% of oncology patients had results within a month of sample collection, while only 56% of rare disease respondents did, with 40% of that cohort waiting longer than a month. The waiting carries the heaviest emotional load: emotional stress during waiting periods was the most common pain point across the whole journey (33%), followed by medical jargon (21%).
Doctors carry the message, and patients research around them.
Doctors remain the dominant information channel (74%), but genetic counselors index significantly higher for rare disease families (38% vs 25%), and 56% of patients are doing their own online research around whatever the care team tells them. Patients ranked speed of receiving a diagnosis as the single most important element of a positive experience (28% ranked it first), with clear communication about what tests are being done and why second (20%).
High self-rated understanding did not close the explanation gaps.
Going in, strong comprehension scores looked like a solved problem: two-thirds of respondents (66%) said they understood their results very well. The gap map read differently. Six in ten flagged at least one thing they wished had been explained better, led by whether results carry implications for family members (31% overall, 38% of the rare disease cohort), ahead of what results mean for treatment and monitoring options (24%) and what they mean for the diagnosis itself (22%). Understanding the result and understanding what it means for your family are different questions, and the second one is where patients most want help.
It completely changed my diagnosis and treatment plan. Before, we thought I had cancer, but the genetic test results showed that I didn't. I continued to treat symptoms because, at the time, there was no treatment, but now there is.
Patient · rare hematological condition
Study Design
N=240patients and caregivers
6 countries
5 languages
Quant + qual, AI-moderated
One routed instrument served both cohorts on matched measures: banded timing at four journey points, multi-select barrier and comprehension batteries, three rank exercises, and open-ended journey narratives with adaptive follow-up probing, moderated under empathy rules written for sensitive health topics. Sourced answer options were translated and piped back in each respondent's language, keeping every measure directly comparable across the six-country base. An 18-day field window produced all 240 verified completes inside 12 days of active fielding.
Sample by segment
Mix
What the guide covered
- Diagnostic journey narrative from first symptoms to confirmed diagnosis, then a second narrative covering care after diagnosis
- Banded timing at four journey points: symptoms to first consult, symptoms to diagnosis, sample to results, results to next care step
- Misdiagnosis and referral loops: initial diagnoses that were later revised, and what led to the correct one
- Barriers and pain points across the journey, each selection spawning its own root-cause probe
- Comprehension of results: what was clear, what was confusing, what patients wished had been explained better
- Information sources around the patient and ranked elements of a positive experience
Who qualified
- Adults across six countries: US, UK, Germany, France, Italy, Spain
- 120 oncology patients and 120 genetic or rare disease patients and caregivers of pediatric patients, hard-quota
- Completed genetic testing tied to the diagnosis, with a testing interaction within the past two years
- Test-type qualification screen admitting only panel-, exome-, or genome-scale genetic testing
Crosstab · Cohort Contrast
Matched journey measures by cohort.
Comparing the two cohorts on matched measures was the analytical core of the study. Every measure was significance-tested across cohorts; the misdiagnosis and turnaround gaps held as structural cohort differences rather than sampling noise. Highlighted row = the headline separation.
| Rare disease (n=120) | Oncology (n=120) | |
|---|---|---|
| Confirmed diagnosis within three months | 44% | 76% |
| More than a year from symptoms to diagnosis | 28% | 3% |
| Initial diagnosis later revised | 48% | 18% |
| Results within a month of sample collection | 56% | 89% |
| Family implications cited as explanation gap | 38% | 23% |
| Treatment meaning cited as explanation gap | 30% | 18% |
Stat-tested · n=120 per cohort · Misdiagnosis and turnaround gaps significant · Six of fourteen barriers also separated significantly
Six barriers separated significantly, all in the rare disease direction.
The six of fourteen measured barriers where the rare disease cohort reported significantly more friction than oncology, shaded by share of cohort citing each.
| Rare disease (n=120) | Oncology (n=120) | |
|---|---|---|
| Specialist wait times | 27% | 13% |
| Long waits for results | 25% | 14% |
| Geographic distance to testing | 18% | 6% |
| Cost and insurance barriers | 17% | 8% |
| Unclear or confusing results | 15% | 7% |
| Sent down the wrong path initially | 15% | 5% |
Voice of Patient and Caregiver
How patients and caregivers describe the journey.
Verbatims from AI-moderated interviews, selected to span cohorts, conditions, and respondent types, each tied to a finding the data quantified.
“From the first symptom to diagnosis, it took two to five years roughly. In my opinion, the main factors that contributed to this length of time was simply because a lot of doctors just kind of dismissed the joint pain.”
“And we also waited for the genetic tests. So I think for genetic tests, we waited six months. So I think we waited almost one year to get to a specialized pediatric neurologist.”
“It did all become very stressful and very overwhelming. I think the main reason for that was uncertainty about the future. And because I have got children, I was worried about being there for them.”
“I was just worried people would look at him differently when they found out the results, and I was also worried about how this would affect my other children in the future.”
“The results helped confirm the type of cancer and showed specific mutations, which guided my treatment choices. It led to a more targeted therapy plan and closer monitoring, moving forward.”
Implications · what the evidence supports
Three readings from the research.
What the client's clinician-facing teams carried out of the study, grounded in patient-reported numbers rather than anecdote.
The misdiagnosis loop is the patient-impact case for earlier, broader testing.
Rare disease patients and caregivers were 2.7 times as likely as oncology patients to report an initial diagnosis that was later revised, and 28% waited more than a year for a confirmed diagnosis. That pairing, misdiagnosis loops plus lost years, frames earlier genome-scale testing as a way to break referral loops rather than as an incremental test-menu upgrade, and it now carries specific patient-reported numbers.
The highest-value communication support sits in three named places.
Family implications (31% overall, 38% among rare disease families), what results mean for treatment and monitoring options (24%), and next steps after results (18%) are the explanation gaps patients most want closed. These are named, rankable content needs that clinician-facing materials and result reports can address directly.
The channel map runs through doctors, with genetic counselors indexing higher for rare disease families.
74% of respondents rely on doctors as their dominant information channel. Genetic counselors index significantly higher for rare disease families (38% vs 25%), and 56% of patients research on their own online around whatever the care team tells them. The channel data shows who carries the patient-impact message and where counseling touchpoints reach the families with the most at stake.
Signals the data flagged
- Speed of receiving a diagnosis ranked first among elements of a positive patient experience (28% ranked it first)
- Emotional stress during waiting periods was the most common pain point across the whole journey (33%)
- Six in ten respondents flagged at least one explanation gap even as 66% said they understood their results very well
Risks the data surfaced
| Family-implication gaps land hardest on rare disease families (38%) | High |
| 40% of rare disease respondents waited longer than a month for results | High |
| Self-reported recall on timing bands, no clinical record linkage | Med |
| Small country cells gate any country-level read (France n=8) | Low |